Title : Radiopharmaceutical Formulation and Preclinical Testing of 68Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial.

Pub. Date : 2021 Jun 16

PMID : 34208516






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The new minigastrin analog DOTA-MGS5 is a promising new candidate for targeting cholecystokinin-2 receptor (CCK2R)-expressing tumors. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid cholecystokinin B receptor Rattus norvegicus
2 The new minigastrin analog DOTA-MGS5 is a promising new candidate for targeting cholecystokinin-2 receptor (CCK2R)-expressing tumors. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid cholecystokinin B receptor Rattus norvegicus